Cardiff Oncology Inc reports results for the quarter ended in March - Earnings Summary

Cardiff Oncology

06/05/2022 22:05

* Cardiff Oncology Inc  CRDF.OQ  reported a quarterly
adjusted
loss of 25 cents​​ per share for the quarter ended in March. The
mean expectation of six analysts for the quarter was for a loss
of 23 cents per share.
    * Revenue rose 2.8% to $74.00 thousand from a year ago; 
analysts
expected $47.17 thousand. 
    * Cardiff Oncology Inc's reported EPS for the quarter was a
loss
of 25 cents​.
    * The mean earnings estimate of analysts had fallen by
about 24.2%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Cardiff Oncology Inc shares had fallen by 46.0% this
quarter and
lost 77.7% so far this year.
    * The company reported a quarterly loss of $11 million.
    * Wall Street's median 12-month price target for Cardiff
Oncology
Inc is $16.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated May 6 at 09:05 p.m.  ​All
figures in US dollars unless otherwise stated